Centre du sein

(Florian) Feasibility Testing of Hydrophobic Carbon Electrodes for Acquisition of Underwater Surface Electromyography Data.

Posada-Quintero H, Noh Y, Eaton-Robb C, Florian JP, Chon KH

Ann Biomed Eng. 2018 May 7

Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?

Chan N, Sager PT, Lawrence J, Ortel T, Reilly P, Berkowitz S, Kubitza D, Eikelboom J, Florian J, Stockbridge N, Rose M, Temple R, Seltzer JH

Am Heart J. 2018 May;199:59-67

The role of the pathology department in the preanalytical phase of molecular analyses.

Susman S, Berindan-Neagoe I, Petrushev B, Pirlog R, Florian IS, Mihu CM, Berce C, Craciun L, Grewal R, Tomuleasa C

Cancer Manag Res. 2018;10:745-753

Experimental cerebral hemispherectomy in rodent models. A systematic review of current literature.

Morosanu CO, Jurca RL, Simonca L, Ilies RF, Moldovan R, Florian IS, Filip GA

Acta Neurobiol Exp (Wars). 2018;78(1):14-20

The caregiver burden in male romantic partners of women with non-metastatic breast cancer: The protective role of couple satisfaction.

Cairo Notari S, Favez N, Notari L, Charvoz L, Delaloye JF

J Health Psychol. 2017 Nov;22(13):1668-1677

The protective effect of a satisfying romantic relationship on women’s body image after breast cancer: a longitudinal study.

Cairo Notari S, Notari L, Favez N, Delaloye JF, Ghisletta P

Psychooncology. 2017 Jun;26(6):836-842

TIE-2 expressing monocytes in human cancers.

Turrini R, Pabois A, Xenarios I, Coukos G, Delaloye JF, Doucey MA

Oncoimmunology. 2017;6(4):e1303585

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK ²²⁄₉₉.

Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A, Swiss Gro

Ann Oncol. 2017 Feb 1;28(2):305-312

Microfluidics-assisted fluorescence in situ hybridization for advantageous human epidermal growth factor receptor 2 assessment in breast cancer.

Nguyen HT, Trouillon R, Matsuoka S, Fiche M, de Leval L, Bisig B, Gijs MA

Lab Invest. 2017 Jan;97(1):93-103

Distress and body image disturbances in women with breast cancer in the immediate postsurgical period: The influence of attachment insecurity.

Favez N, Cairo Notari S, Charvoz L, Notari L, Ghisletta P, Panes Ruedin B, Delaloye JF

J Health Psychol. 2016 Dec;21(12):2994-3003

SAKK ²⁴⁄₀₉: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III tr

Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Swiss Group for C

BMC Cancer. 2016 Oct 10;16(1):780

[Hormone therapy in invasive breast cancer : update 2016].

Zurcher JP, Stravodimou A, Zaman K

Rev Med Suisse. 2016 Sep 21;12(531):1580-1583

First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Rageth CJ, O’Flynn EA, Comstock C, Kurtz C, Kubik R, Madjar H, Lepori D, Kampmann G, Mundinger A, Baege A, Decker T, Hosch S, Tausch C, Delaloye JF, Morris E, Varga Z

Breast Cancer Res Treat. 2016 Sep;159(2):203-13

First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Rageth CJ, O’Flynn EA, Comstock C, Kurtz C, Kubik R, Madjar H, Lepori D, Kampmann G, Mundinger A, Baege A, Decker T, Hosch S, Tausch C, Delaloye JF, Morris E, Varga Z

Breast Cancer Res Treat. 2016 Sep;159(2):203-13

[BRCA mutations: from Angelina Jolie to specific therapies].

Lopez VA, Stravodimou A, Unger S, Perey L, Zaman K

Rev Med Suisse. 2016 May 18;12(519):973-4, 976-7

Adjuvant ovarian function suppression and cognitive function in women with breast cancer.

Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Feng Y, Price KN, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Ahles T, Fleming GF, Bernhard J

Br J Cancer. 2016 Apr 26;114(9):956-64

A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response.

Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, Raffoul W, Delaloye JF, Treboux A, Fiche M, Vilo J, Ayyanan A, Brisken C

Cancer Cell. 2016 Mar 14;29(3):407-422

Reduction of Respiratory Motion During PET/CT by Pulsatile-Flow Ventilation: A First Clinical Evaluation.

Prior JO, Péguret N, Pomoni A, Pappon M, Zeverino M, Belmondo B, Lovis A, Ozsahin M, Vienne M, Bourhis J

J Nucl Med. 2016 Mar;57(3):416-9

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J, IBIS-II investigators.

Lancet. 2016 Feb 27;387(10021):866-73

Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer.

Dupouy DG, Ciftlik AT, Fiche M, Heintze D, Bisig B, de Leval L, Gijs MA

Sci Rep. 2016 Feb 9;6:20277

Apnea-like suppression of respiratory motion: First evaluation in radiotherapy.

Péguret N, Ozsahin M, Zeverino M, Belmondo B, Durham AD, Lovis A, Simons J, Long O, Duclos F, Prior J, Denys A, Beigelman C, Sozzi WJ, Grant K, Gautier-Dechaud V, Peters S, Vienne M, Moeckli R, Bourhis J

Radiother Oncol. 2016 Feb;118(2):220-6

[Palliative care: a death sentence or hope? When do you talk about it?].

Mazzocato C

Rev Med Suisse. 2016 Jan 27;12(503):194-5

[Ultrasound for Breast Cancer Screening: an Effective Tool in a Personalized Screening].

Meuwly JY

Praxis (Bern 1994). 2015 Dec 9;104(25):1399-404

Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations.

Caiata-Zufferey M, Pagani O, Cina V, Membrez V, Taborelli M, Unger S, Murphy A, Monnerat C, Chappuis PO

Genet Med. 2015 Sep;17(9):726-32

Fulvestrant with or without selumetinib, a MEK ¹⁄₂ inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK ²¹⁄₀₈.

Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Rudolf CB, Hawle H, Rondeau S, Neven P

Eur J Cancer. 2015 Jul;51(10):1212-20

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair OM, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber RD, Goldhirsch A, Korde L, Azim HA Jr,

Breast. 2015 Jun;24(3):201-7

Tumor-infiltrating lymphocytes in triple-negative breast cancer: a biomarker for use beyond prognosis?

Tsoutsou PG, Bourhis J, Coukos G

J Clin Oncol. 2015 Apr 10;33(11):1297-8

Angiogenic activity of breast cancer patients’ monocytes reverted by combined use of systems modeling and experimental approaches.

Guex N, Crespo I, Bron S, Ifticene-Treboux A, Faes-Van’t Hull E, Kharoubi S, Liechti R, Werffeli P, Ibberson M, Majo F, Nicolas M, Laurent J, Garg A, Zaman K, Lehr HA, Stevenson BJ, Rüegg C, Coukos G, Delaloye JF, Xenarios I, Doucey MA

PLoS Comput Biol. 2015 Mar;11(3):e1004050

[Palliative Care in Nursing Homes: Characteristics and Specificities].

Gremaud G, Mazzocato C

Praxis (Bern 1994). 2015 Feb 25;104(5):245-50

Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?

Guiu S, Wolfer A, Jacot W, Fumoleau P, Romieu G, Bonnetain F, Fiche M

Crit Rev Oncol Hematol. 2014 Dec;92(3):235-57

[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS’ guidelines in France].

MacGrogan G, Mathieu MC, Poulet B, Penault-Llorca F, Vincent-Salomon A, Roger P, Treilleux I, Valent A, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Gar

Ann Pathol. 2014 Oct;34(5):366-72

[2014 update of the GEFPICS’ recommendations for HER2 status determination in breast cancers in France].

Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A, Mathieu MC, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Gen

Ann Pathol. 2014 Oct;34(5):352-65

[Endocrine therapy resistance in metastatic breast cancer: mechanisms and clinical implications].

Orcurto A, Odermatt R, Stravodimou A, Wolfer A

Rev Med Suisse. 2014 May 21;10(431):1102-6

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.

Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price KN, Gelber RD, Goldhirsch A, Coates AS, Aebi S

Breast Cancer Res Treat. 2014 Apr;144(2):321-9

Clinician characteristics, communication, and patient outcome in oncology: a systematic review.

De Vries AM, de Roten Y, Meystre C, Passchier J, Despland JN, Stiefel F

Psychooncology. 2014 Apr;23(4):375-81

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series.

Stravodimou A, Zaman K, Voutsadakis IA

ISRN Oncol. 2014;2014:289836

Psycho-oncological interventions and psychotherapy in the oncology setting.

de Vries M, Stiefel F

Recent Results Cancer Res. 2014;197:121-35

Psychodynamic interventions in cancer care I: psychometric results of a randomized controlled trial.

Ludwig G, Krenz S, Zdrojewski C, Bot M, Rousselle I, Stagno D, Luethi F, Leyvraz S, Stiefel F

Psychooncology. 2014 Jan;23(1):65-74

Psychodynamic interventions in cancer care II: a qualitative analysis of the therapists’ reports.

Krenz S, Godel C, Stagno D, Stiefel F, Ludwig G

Psychooncology. 2014 Jan;23(1):75-80

Radiotherapy options after breast-conserving surgery: how can selection of patients be refined?

Tsoutsou PG, Jeanneret Sozzi W, Ozsahin M, Delaloye JF, Bourhis J

J Clin Oncol. 2013 Dec 20;31(36):4570-1

Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss.

Zaman K, Thuerlimann B, Aebi S

J Clin Oncol. 2013 Sep 20;31(27):3440-1

Assessment of needs, health-related quality of life, and satisfaction with care in breast cancer patients to better target supportive care.

Brédart A, Kop JL, Griesser AC, Fiszer C, Zaman K, Panes-Ruedin B, Jeanneret W, Delaloye JF, Zimmers S, Berthet V, Dolbeault S

Ann Oncol. 2013 Aug;24(8):2151-8

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.

Jacot W, Fiche M, Zaman K, Wolfer A, Lamy PJ

Biochim Biophys Acta. 2013 Aug;1836(1):146-57

TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors.

Ibberson M, Bron S, Guex N, Faes-van’t Hull E, Ifticene-Treboux A, Henry L, Lehr HA, Delaloye JF, Coukos G, Xenarios I, Doucey MA

Clin Cancer Res. 2013 Jul 1;19(13):3439-49

Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.

Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, Créhange G, Coutant C, Fumoleau P, Coudert B

Breast. 2013 Jun;22(3):301-8

[Endocrine therapy in breast cancer: efficacy and adverse events].

Odermatt R, Wolfer A, Zaman K

Rev Med Suisse. 2013 May 22;9(387):1090-4

Progesterone/RANKL is a major regulatory axis in the human breast.

Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, Yalcin-Ozuysal O, Brisken C

Sci Transl Med. 2013 Apr 24;5(182):182ra55

Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas.

Lehr HA, Rochat C, Schaper C, Nobile A, Shanouda S, Vijgen S, Gauthier A, Obermann E, Leuba S, Schmidt M, C CR, Delaloye JF, Simiantonaki N, Schaefer SC

Mod Pathol. 2013 Mar;26(3):336-42

Nomograms predicting locoregional recurrence in the subtype era of breast cancer.

Tsoutsou PG, Jeanneret Sozzi W, Matzinger O, Ozsahin M

J Clin Oncol. 2013 Feb 10;31(5):647-8

Working alliance in communication skills training for oncology clinicians: a controlled trial.

Meystre C, Bourquin C, Despland JN, Stiefel F, de Roten Y

Patient Educ Couns. 2013 Feb;90(2):233-8

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.

Bonnefoi H, Zaman K, Debled M, Fiche M, Fournier M, Nobahar M, Pierga JY, Koch KM, Bartlett J, Zimmer A, Marreaud S, Bogaerts J, Cameron D

Eur J Cancer. 2013 Jan;49(2):281-9

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS

Ann Oncol. 2012 Dec;23(12):2997-3006

[Indications and techniques of reconstruction after mastectomy].

Koch N, Delaloye JF, Raffoul W

Rev Med Suisse. 2012 Oct 24;8(359):2003-4, 2006

[Direct support measures reduce psychological stress in family caregivers].

Rège-Walther M, Mazzocato C, Peytremann-Bridevaux I

Praxis (Bern 1994). 2012 Oct 17;101(21):1383-4

Tumor architecture exerts no bias on nuclear grading in breast cancer diagnosis.

Mora B, Bombari D, Schaefer SC, Schmidt M, Delaloye JF, Mast F, Lehr HA

Virchows Arch. 2012 Oct;461(4):399-403

Fertility preservation in cancer patients. Review of the French speaking part of Switzerland and recommendations for different situations.

Wunder D, Perey L, Réseau Romand Cancer et Fertilité., Achtari C, Ambrosetti A, Bellavia M, Delaloye JF, de Ziegler D, Gumy-Pause F, Helg C, Ketterer N, Petignat P, Primi MP, Rosselet-Christ A, Zaman K

Swiss Med Wkly. 2012;142:w13645

Validation of the 34-item Supportive Care Needs Survey and 8-item breast module French versions (SCNS-SF34-Fr and SCNS-BR8-Fr) in breast cancer patients.

Brédart A, Kop JL, Griesser AC, Zaman K, Panes-Ruedin B, Jeanneret W, Delaloye JF, Zimmers S, Jacob A, Berthet V, Fiszer C, Dolbeault S

Eur J Cancer Care (Engl). 2012 Jul;21(4):450-9

Oncology clinicians’ defenses and adherence to communication skills training with simulated patients: an exploratory study.

Bernard M, de Roten Y, Despland JN, Stiefel F

J Cancer Educ. 2012 Jun;27(3):399-403

The impact of communication skills training in oncology: a linguistic analysis.

Singy P, Bourquin C, Sulstarova B, Stiefel F

J Cancer Educ. 2012 Jun;27(3):404-8

Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK ²¹⁄₀₇).

Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S, Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2012 Jun;23(6):1474-81

[Breast cancer and obesity, a dangerous relation].

Zaman K, Bodmer A, Pralong F, Castiglione-Gertsch M

Rev Med Suisse. 2012 May 23;8(342):1101-4

Response to “Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.” (Int J Radiat Oncol Biol Phys 2011;80:398-402).

Tsoutsou PG, Jeanneret Sozzi W, Ozsahin M

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):519; author reply 519-20

Personalizing locoregional treatment in the adjuvant setting of early breast cancer on the basis of molecular background: an exciting enigma.

Tsoutsou PG, Sozzi WJ, Matzinger O, Ozsahin M

J Clin Oncol. 2011 Dec 10;29(35):4721-2; author reply 4723-4

Interactions between cancer stem cells and their niche govern metastatic colonization.

Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J

Nature. 2011 Dec 7;481(7379):85-9

Dermatofibrosarcoma presenting as a nodule in the breast of a 75-year-old woman: a case report.

Cottier O, Fiche M, Meuwly JY, Delaloye JF

J Med Case Rep. 2011 Oct 5;5:503

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A

Ann Oncol. 2011 Oct;22(10):2216-26

What makes a good pathology report?

Nobile A, Treboux A, Delaloye JF, Zaman K, Jeanneret-Sozzi W, Schaefer SC, Lehr HA

Eur J Cancer. 2011 Sep;47(14):2082-3

Asymmetric cancer cell division regulated by AKT.

Dey-Guha I, Wolfer A, Yeh AC, G Albeck J, Darp R, Leon E, Wulfkuhle J, Petricoin EF 3rd, Wittner BS, Ramaswamy S

Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12845-50

Breast sarcomas: current and future perspectives.

Voutsadakis IA, Zaman K, Leyvraz S

Breast. 2011 Jun;20(3):199-204

A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer.

Zaman K, Durando X, Baurain JF, Humblet Y, Mazzeo F, Bostnavaron M, Meheust N, Monnoyer-Favrel S, Machiels JP, Bauer J

Breast Cancer Res Treat. 2011 Jun;127(3):689-96

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R, EORTC 10994/BIG 1-00 Study Investigat

Lancet Oncol. 2011 Jun;12(6):527-39

Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors.

Laurent J, Hull EF, Touvrey C, Kuonen F, Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC, Fagiani E, Zaman K, Stupp R, Shibuya M, Delaloye JF, Christofori G, Ruegg C

Cancer Res. 2011 Jun 1;71(11):3781-91

Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK ²³⁄₀₃).

Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thuerlimann B, Swiss Group for Clinical Cancer Research (SAKK).

Endocr Relat Cancer. 2011 Apr;18(2):257-64

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK ²⁴⁄₀₆).

Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K, Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2011 Jan;22(1):80-5

Protein-binding microarray analysis of tumor suppressor AP2α target gene specificity.

Kerschgens J, Renaud S, Schütz F, Grasso L, Egener-Kuhn T, Delaloye JF, Lehr HA, Vogel H, Mermod N

PLoS One. 2011;6(8):e22895

An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4’-hydroxylated metabolites in breast cancer patients.

Dahmane E, Mercier T, Zanolari B, Cruchon S, Guignard N, Buclin T, Leyvraz S, Zaman K, Csajka C, Decosterd LA

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Dec 15;878(32):3402-14

[Ultrasonography-guided drainage should be considered as the first-line approach for the treatment of breast abscess].

Delaloye JF, Capoccia Brugger R, Ifticene Treboux A, Anaye A, Meuwly JY

Rev Med Suisse. 2010 Oct 27;6(268):2010-2

Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates.

Yalcin-Ozuysal O, Fiche M, Guitierrez M, Wagner KU, Raffoul W, Brisken C

Cell Death Differ. 2010 Oct;17(10):1600-12

[Cardiologic follow up of an oncologic patient].

Zaugg Longchamp D, Zaman K, Aebischer N

Rev Med Suisse. 2010 Jun 2;6(251):1133-4, 1136-9

[Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks].

Wagner AD, Zaman K, Peters S, Montemurro M, Leyvraz S

Rev Med Suisse. 2010 May 26;6(250):1070-3

Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.

Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, Moscardo CL, Lemanski C, Coelho M, Rosenstein B, Fenoglietto P, Crompton NE, Ozsahin M

Lancet Oncol. 2010 Mar;11(3):258-65

Improving breast cancer education: the case of an evolving multidisciplinary module for undergraduate medical students (Lausanne Medical School, 1993-2008).

Fiche M, Lepori D, Guntern D, Jucker-Kupper P, Jeanneret W, Zaman K, Vadot S, Delaloye JF

J Cancer Educ. 2010 Mar;25(1):101-5

MYC regulation of a “poor-prognosis” metastatic cancer cell state.

Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3698-703

Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider.

Tsoutsou PG, Belkacemi Y, Gligorov J, Kuten A, Boussen H, Bese N, Koukourakis MI, Association of Radiotherapy and Oncology in the Mediterranean area (AROME).

Oncologist. 2010;15(11):1169-78

Severe anaphylactic shock to Patent Blue V with cardiac arrest during breast carcinoma surgery with lymphatic mapping.

Thierrin L, Steiger D, Zuber JP, Spertini F, Brunisholz Y, Delaloye JF

Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):140-1